Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197944 · ClinicalTrials.gov registry record · Phase 3
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
A Phase 3 study of Short Bowel Syndrome, sponsored by Zealand Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 17
- Study locations
NCT07197944: Recruiting Phase 3 study of Short Bowel Syndrome, sponsored by Zealand Pharma.
NCT07197944 is a Phase 3 study of Short Bowel Syndrome that is actively recruiting participants, run by Zealand Pharma. The registered enrollment target is 90 participants, below the 180-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (50% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07197944, a Phase 3 study of Short Bowel Syndrome, is actively recruiting participants, sponsored by Zealand Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Glepaglutide
Study Locations (17)
Other
- Rigshospitalet-Blegdamsvej 9 - Copenhagen
- AP-HP - Hôpital Beaujon - Clichy
- Charité - Universitätsmedizin Berlin - Berlin
- Universitätsklinikum Bonn - Bonn
- Oslo Universitetssykehus HF, Ullevål - Oslo
- Sahlgrenska Universitets sjukhuset - Gothenburg
- Karolinska Universitetssjukhuset Solna - Solna
Madrid
- Hospital General Universitario Gregorio Marañon - Madrid
- Hospital Universitario 12 de Octubre - Madrid
Missouri
- Washington University Center for Advanced Medicine - St Louis
Vienna
- Universitätsklinikum AKH Wien - Vienna
Mecklenburg-Vorpommern
- Universitätsmedizin Rostock - Rostock
Saxony
- Eugastro Klinische Studien GmbH - Leipzig
Lazio
- Fondazione Policlinico Universitario A. Gemelli IRCCS - PPDS - Rome
Gelderland
- Radboud Universitair Medisch Centrum - Nijmegen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2032-02-28 |
| Phase | Phase 3 |
What NCT07197944 shows while recruiting
NCT07197944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 180-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07197944 lists 17 locations in 10 states (Other, Madrid, Missouri).
Frequently Asked Questions
What is clinical trial NCT07197944 about?
NCT07197944 is a clinical study titled "Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS". The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848...
What is the current status of trial NCT07197944?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2026-02-11. Estimated completion is 2032-02-28.
What conditions does trial NCT07197944 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT07197944?
The interventions under investigation include: Placebo (OTHER), Glepaglutide (DRUG).
Who is sponsoring clinical trial NCT07197944?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197944 being conducted?
This trial has 17 study locations across Missouri, Vienna, Mecklenburg-Vorpommern, Saxony, Lazio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07197944's enrollment target sits among peer trials
90 8th of 17 higher than 10 of 17 other Short Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Short Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
ACTIVE NOT RECRUITING · Phase 3
-
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
ACTIVE NOT RECRUITING · Phase 3
-
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
COMPLETED · Phase 3
-
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
COMPLETED · Phase 3
-
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI